Amendments to the Claims

This claim listing will replace all prior versions of claims and claim listings in the application:

WHAT IS CLAIMED:

1. (Previously presented) A compound structurally represented by Formula I

$$R^1$$

Formula (I)

or pharmaceutically acceptable salts thereof wherein:

 R^1 is

-CH₂N
$$R^3R^4$$
,

 R^2 is

-Hydrogen,

-NH- (C_1-C_6) alkyl,

-NH-(C₁-C₄) alkylene-phenyl,

-NH(C₃-C₆)cycloakyl,

 $-NR^3R^4$,

$$-N$$
 N
 $-CH_3$

$$-N$$

Serial No. 10/598262

$$-N$$

wherein;

R³ is hydrogen,

-(C₁-C₄) alkyl,

R⁴ is

 $-(C_1-C_4)$ alkyl,

-(C₁-C₄) alkylene -phenyl,

wherein R^3 and R^4 can cyclize to form, together with the nitrogen to which they are attached, a five or six-membered ring, wherein optionally one of the carbons of the ring formed by said nitrogen, R^3 , and R^4 , is replaced by a nitrogen or oxygen, and wherein said ring is optionally further substituted by R^5 , and

R⁵ is hydrogen,

-(C₁-C₄) alkyl, wherein optionally R⁵ forms a 3 to five membered ring with the nitrogen containing ring to which it is attached,

-(C₁-C₄) alkylene –N-pyrrolidinyl,

 $-(C_1-C_4)$ alkylene -N- piperidinyl;

is —N—CH₃

provided that when R1 is $-CH_2NR^3R^4$ or $-CONR^3R^4$, then R2 is

2. (Original) A compound structurally represented by Formula II,

or pharmaceutically acceptable salts thereof wherein:

Z is -carbonyl-, or -CH₂-,

 R^2 is


-Hydrogen,

-NH- (C_1-C_6) alkyl,

-NH-(C₁-C₄) alkylene-phenyl,

-NH(C₃-C₆)cycloakyl,

 $-NR^3R^4$.



wherein:

R³ is hydrogen,

-(C₁-C₄) alkyl,

 R^4 is

-(C₁-C₄) alkylene -phenyl,

wherein R^3 and R^4 can cyclize to form, together with the nitrogen to which they are attached, a five or six-membered ring, wherein optionally one of the carbons of the ring formed by said nitrogen, R^3 , and R^4 , is replaced by a nitrogen or oxygen, and wherein said ring is optionally further substituted by R^5 , and

R⁵ is hydrogen,

-(C₁-C₄) alkyl, wherein optionally R⁵ forms a 3 to five membered ring with the nitrogen containing ring to which it is attached,

-(C₁-C₄) alkylene –N-pyrrolidinyl,


-(C₁-C₄) alkylene –N- piperidinyl.

3. (Original) The compound of claim 1, wherein R¹ is CONR³R⁴, and R³ and R⁴ cyclize to form, together with the nitrogen to which they are attached, a five membered ring, and said ring is further substituted by -CH₂- pyrrolidinyl.

- 4. (Original) The compound of claim 1, wherein R¹ is CH₂NR³R⁴, and R³ and R⁴ cyclize to form, together with the nitrogen to which they are attached, a five membered ring, and said ring is further substituted by -CH₂- pyrrolidinyl.
- 5. (Original) The compound of claim 3 wherein R² is N R³R⁴, and R³ and R⁴ cyclize to form, together with the nitrogen to which they are attached, a five membered ring.
- 6. (Original) The compound of claim 4 wherein R² is N R³R⁴, and R³ and R⁴ cyclize to form, together with the nitrogen to which they are attached, a five membered ring.
- 7. (Previously presented) The compound of claim 1, further represented by any one of the formula selected from the group consisting of:

| Example Number | |
|-------------------|---------------|
| 1 | Chiral Chiral |
| 2 | Chiral Chiral |
| 3 | Chiral Chiral |

| 4 | Chiral Chiral |
|---|---|
| 5 | Chiral O N N N N N N N N N N N N |
| 6 | Chiral |
| 8 | |
| 9 | Chiral N |



or a pharmaceutically acceptable salt thereof.

8. (Previously presented) A pharmaceutical composition which comprises a compound of claim 1 and a pharmaceutically acceptable carrier.

- 9. (Canceled)
- 10. (Canceled)
- 11. (Previously presented) A method for treatment or prevention of obesity which comprises administering to a subject in need of such treatment or prevention an effective amount of a compound of Claim 1.
- 12. (Canceled)
- 13. (Canceled)
- 14. (Canceled)
- 15. (Canceled)
- 16. (Previously presented) A compound selected from the group consisting of:

| Example Number | |
|-------------------|--|
| 7 | |
| 10 | |
| 11 | |

or a pharmaceutically acceptable salt thereof.